Initiation of HTL1071 trial triggers $10m payment to Heptares
The first subject has been dosed with immuno-oncology candidate HTL1071 (AZD4635) in a Phase I clinical study, triggering a US$10 million payment toHeptares from AstraZeneca.
Click on this link for more information.
